Clinical Trials Browser

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

83 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT07170995 2025-11-18

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Recruiting

460 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04215978 2025-10-03

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1 Completed

204 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Terminated

377 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04746924 2025-06-24

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Phase 3 Active not recruiting

662 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

60 enrolled

DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT05840016 2025-05-02

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

532 enrolled

Thoracic

Advanced Squamous Non Small Cell Lung Cancer

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Phase 1/2 Recruiting

120 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase 3 Recruiting

392 enrolled

Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

NCT04005716 2025-02-28

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3 Completed

457 enrolled 20 charts

Thoracic

Small Cell Lung Carcinoma

NCT03358875 2025-02-10

RATIONALE-303

Phase 3 Completed

805 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03663205 2025-02-04

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3 Completed

334 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04866017 2024-10-31

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3 Terminated

63 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03594747 2024-10-26

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Phase 3 Completed

360 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04952597 2024-10-26

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Phase 2 Completed

126 enrolled 19 charts

Thoracic

Limited Stage Small Cell Lung Cancer

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Phase 2 Completed

54 enrolled

Thoracic

Lung Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

642 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05718167 2023-02-14

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Phase 3 Unknown

570 enrolled

Thoracic

Advanced Squamous Non-Small Cell Lung Carcinoma

NCT03745222 2020-07-15

RATIONALE001

Phase 3 Terminated

1 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

KontRASt-R

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

KontRASt-01

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

A Study of SKB518 in Patients With Lung Cancer

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

RATIONALE-303

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

AdvanTIG-306

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

RATIONALE001